natgillin/translations-raw huggingface dataset:
Compared to placebo, patients with rheumatic diseases treated with etanercept had a significantly higher incidence of injection site reactions (36% vs. 9%). 
V primerjavi s placebom je bila pri bolnikih z revmatskimi obolenji, zdravljenih z etanerceptom, incidenca reakcij na mestu injiciranja pomembno večja (36 % proti 9 %).
For psoriatic arthritis patients with multiple joint involvement, Benepali can improve your ability to do normal daily activities. 
Pri bolnikih s psoriatičnim artritisom in prizadetostjo več sklepov lahko zdravilo Benepali izboljša sposobnost opravljanja običajnih vsakdanjih dejavnosti.
Detailed instructions on how to inject Benepali are provided in section 7, “Instructions for use”. 
Podrobna navodila o injiciranju zdravila Benepali so v poglavju 7, "Navodila za uporabo".
• Cancer: Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given Benepali. 
• Rak: Preden boste prejeli zdravilo Benepali, povejte zdravniku, če imate ali ste kdaj imeli limfom (vrsta krvnega raka) ali drugo obliko raka.
Uncommon ≥ 1/1,000 to 
Občasni ≥ 1/1.000 do
Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) method, which may detect ELISA-reactive degradation products, as well as the parent compound. 
Koncentracije etanercepta v serumu so bile določene z metodo encimskega imunskega testa (ELISA), ki zazna tako ELISA reaktivne razgradne produkte kot tudi izhodno snov.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE
TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). 
TNF in limfotoksin sta provnetna citokina, ki se vežeta na dva različna tipa receptorjev na površini celice: 55-kilodaltonske (p55) in 75-kilodaltonske (p75) receptorje TNF.
The long-term safety of etanercept in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established. 
Varnost dolgotrajnega kombiniranega zdravljenja z etanerceptom in drugimi imunomodulirajočimi antirevmatičnimi zdravili (DMARD - Disease-Modifying AntiRheumatic Drugs) ni bila ugotovljena.
Benepali may be stored at temperatures up to a maximum of 25°C for a single period of up to four weeks; after which, it should not be refrigerated again. 
Zdravilo Benepali se lahko shranjuje pri temperaturi do največ 25 °C za enkratno obdobje do štirih tednov, po katerem se ga ne sme več vrniti v hladilnik.
If Benepali has no effect on your condition after 12 weeks, your doctor may tell you to stop using this medicine. 
Če zdravilo Benepali po 12 tednih nima nobenega učinka na vašo bolezen, vam zdravnik lahko naroči, da to zdravilo nehate uporabljati.
The safety and efficacy of etanercept in patients with immunosuppression have not been evaluated. 
Varnost in učinkovitost etanercepta pri bolnikih z imunosupresijo nista bili ovrednoteni.
ACR 20 and 50 responses were higher in patients treated with etanercept at 3 and 6 months than in patients treated with placebo (ACR 20: etanercept 62% and 59%, placebo 23% and 11% at 3 and 6 months, respectively: ACR 50: etanercept 41% and 40%, placebo 8% and 5% at months 3 and 6, respectively; p < 0.01 etanercept vs. placebo at all timepoints for both ACR 20 and ACR 50 responses). 
Odstotek bolnikov, ki so po 3 oziroma 6 mesecih dosegli odziv ACR 20 ali ACR 50, je bil v skupini bolnikov, ki so bili zdravljeni z etanerceptom, večji kot pri bolnikih, ki so prejemali placebo (ACR 20 po 3 oz. 6 mesecih: etanercept 62 % oz. 59 %, placebo 23 % oz. 11 %; ACR 50 po 3 oz. 6 mesecih: etanercept 41 % oz. 40 %, placebo 8 % oz. 5 %; p < 0,01 za etanercept proti placebu v vseh časovnih točkah, tako za odziv ACR 20 kot za odziv ACR 50).
Such patients should be investigated urgently, including full blood count; if blood dyscrasias are confirmed, Benepali should be discontinued. 
Take bolnike je treba nemudoma pregledati, vključno s pregledom celotne krvne slike, in v primeru krvne diskrazije prekiniti zdravljenje z zdravilom Benepali.
Paediatric patients with juvenile idiopathic arthritis The safety and efficacy of etanercept were assessed in a two-part study in 69 children with polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types (polyarthritis, pauciarthritis, systemic onset). 
Pediatrični bolniki z juvenilnim idiopatskim artritisom Varnost in učinkovitost etanercepta je bila ugotovljena v dvodelni študiji pri 69 otrocih s poliartikularnim potekom juvenilnega idiopatskega artritisa z različnimi tipi nastopa bolezni (poliartritis, oligoartritis, sistemski nastop).
• Nervous system and eye disorders: Tell your doctor if you or the child have multiple sclerosis, optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the spinal cord). 
• Bolezni živčevja in očesne bolezni: Povejte zdravniku, če imate vi ali otrok multiplo sklerozo, optični nevritis (vnetje očesnega živca) ali transverzni mielitis (vnetje hrbtnega mozga).
• A needle-free demonstration device 
• Vadbeni pripomoček brez igle
One rheumatoid arthritis patient mistakenly self-administered 62 mg etanercept subcutaneously twice weekly for 3 weeks without experiencing undesirable effects. 
En bolnik z revmatoidnim artritisom si je pomotoma subkutano injiciral 62 mg etanercepta 2-krat tedensko 3 tedne, pri tem pa ni prišlo do pojava nobenega neželenega učinka.
Patients with a significant exposure to varicella virus should temporarily discontinue Benepali therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin. 
Bolniki, ki so zelo izpostavljeni virusu noric, naj začasno prekinejo zdravljenje z zdravilom Benepali, v poštev pa pridejo tudi za profilaktično zdravljenje z imunoglobulinom proti virusu varicella-zoster.
Both TNFRs exist naturally in membrane-bound and soluble forms. 
Oboji receptorji TNF v naravi obstajajo v dveh oblikah, tj. vezani na membrano in v topni obliki.
Treatment of active and progressive psoriatic arthritis in adults when the response to previous diseasemodifying antirheumatic drug therapy has been inadequate. 
Zdravljenje aktivnega in progresivnega psoriatičnega artritisa pri odraslih, če je bil odziv na zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili nezadosten.
Etanercept was considered to be non-genotoxic from a battery of in vitro and in vivo studies. 
Etanercept se ni izkazal za genotoksičnega v vrsti študij in vivo in in vitro.
• Severe rash, itching, or hives (elevated patches of red or pale skin that often itch) 
• hud izpuščaj, srbenje ali koprivnica (rdeče ali blede kožne spremembe nad ravnijo kože, ki pogosto srbijo).
Efficacy response in placebo-controlled nr-AxSpa study: Percent of patients achieving endpoints Double-Blind Clinical 
Odziv glede učinkovitosti v s placebom nadzorovani študiji nr-AxSpa: Odstotek bolnikov, ki so dosegli opazovane dogodke
Non-melanoma skin cancers* (see section 4.4) 
nemelanomski kožni rak* (glejte poglavje 4.4)
Combining the results of controlled clinical trials, more cases of NMSC were observed in patients receiving etanercept compared with control patients, particularly in patients with psoriasis. 
Pri združevanju rezultatov nadzorovanih kliničnih preskušanj so opazili več primerov NMSC pri bolnikih, ki so prejemali etanercept, kot pri kontrolnih bolnikih, še zlasti pri bolnikih s psoriazo.
Responses of patients with ankylosing spondylitis in a placebo-controlled trial Percent of Patients 
Odzivi bolnikov z ankilozirajočim spondilitisom v preskušanju, nadzorovanem s placebom Odstotek bolnikov
The efficacy of etanercept was assessed in a randomised, double-blind, placebo-controlled study in 205 patients with psoriatic arthritis. 
Učinkovitost etanercepta je bila ocenjena v randomizirani, dvojno slepi in s placebom nadzorovani študiji pri 205 bolnikih s psoriatičnim artritisom.
Patients were observed off treatment for the occurrence of rebound (PASI ≥ 150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24). 
Bolnike so brez zdravljenja spremljali glede preobratnih znakov (PASI ≥ 150 % izhodiščnega) in časa do recidiva (opredeljenega kot izginotje vsaj polovice izboljšanja, doseženega med izhodiščem in 24. tednom).
Several adverse events were reported more commonly in 69 juvenile idiopathic arthritis patients receiving 3 months of etanercept compared to the 349 adult rheumatoid arthritis patients. 
Nekateri neželeni učinki so bili pogosteje opaženi pri 69 bolnikih z juvenilnim idiopatskim artritisom, ki so etanercept prejemali 3 mesece, kot pri 349 odraslih bolnikih z revmatoidnim artritisom.
EU/1/15/1074/006 multipack of 8 pre-filled syringes (2 packs of 4) EU/1/15/1074/007 multipack of 24 pre-filled syringes (6 packs of 4) 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/15/1074/006 večodmerno pakiranje z 8 napolnjenimi injekcijskimi brizgami (2 pakiranji po 4) EU/1/15/1074/007 večodmerno pakiranje s 24 napolnjenimi injekcijskimi brizgami (6 pakiranj po 4)
In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of etanercept and methotrexate did not result in unexpected safety findings, and the safety profile of etanercept when given in combination with methotrexate was similar to the profiles reported in studies of etanercept and methotrexate alone. 
V dveletnem nadzorovanem kliničnem preskušanju pri bolnikih z revmatoidnim artritisom ni bilo pri kombiniranem zdravljenju z etanerceptom in metotreksatom nobenih nepričakovanih ugotovitev glede varnosti; varnostni profil etanercepta pri kombiniranem zdravljenju z metotreksatom je bil podoben varnostnemu profilu, ki je bil ugotovljen pri monoterapiji z etanerceptom oziroma metotreksatom.
Dimeric soluble receptors, such as etanercept, possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors. 
Topni dimerni receptorji, kot je etanercept, imajo večjo afiniteto za TNF kot monomerni receptorji in so veliko bolj učinkoviti kompetitivni antagonisti vezave TNF na celične receptorje.
Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis 
Psoriatični artritis, ankilozirajoči spondilitis in radiografsko nezaznavni aksialni spondilartritis
The recommended dose is 50 mg etanercept administered once weekly (see section 5.1). 
Priporočeni odmerek je 50 mg etanercepta enkrat na teden (glejte poglavje 5.1).
• Signs of cancers: Cancers may affect any part of the body including the skin and blood, and possible signs will depend on the type and location of the cancer. 
• znaki rakavih obolenj: Rak lahko prizadene kateri koli del telesa, vključno s kožo in krvjo.
Do not recap the needle. 
Pokrovčka ne natikajte nazaj na iglo.
Physicians should use caution when using Benepali in patients who also have moderate to severe alcoholic hepatitis. 
Zdravniki naj bodo pazljivi, kadar uporabljajo zdravilo Benepali pri bolnikih, ki imajo tudi zmeren do hud alkoholni hepatitis.
A single 50 mg/ml injection of etanercept was found to be bioequivalent to two simultaneous injections of 25 mg/ml. 
Ugotovili so, da je ena 50 mg/ml injekcija etanercepta bioekvivalentna dvema sočasnima injekcijama po 25 mg/ml.
In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with etanercept developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment. 
V nadzorovanih preskušanjih bolnikov s psoriazo v plakih so se reakcije na mestu injiciranja v prvih 12 tednih zdravljenja pojavile pri približno 13,6 % bolnikov, zdravljenih z etanerceptom, in pri 3,4 % bolnikov, ki so dobivali placebo.
There were no differences in rates of infection among patients treated with etanercept and those treated with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. 
V stopnjah pogostnosti okužb med bolniki, zdravljenimi z etanerceptom, in tistimi, ki so prejemali placebo za zdravljenje psoriaze v plakih, v preskušanjih, nadzorovanih s placebom, ki so trajala do 24 tednov, ni bilo razlik.
Benepali treatment may increase mortality in patients with established sepsis. 
Zdravljenje z zdravilom Benepali lahko zveča smrtnost pri bolnikih z dokazano sepso.
The proportion of patients treated with etanercept who developed anticardiolipin antibodies was similarly increased compared to placebotreated patients. 
Delež bolnikov, ki so razvili protitelesa proti kardiolipinu, je bil podobno povečan pri etanerceptu v primerjavi s placebom.
In plaque psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in psoriatic lesions compared with levels in uninvolved skin. 
Pri psoriazi v plakih se zaradi infiltracije vnetnih celic (vključno s celicami T) v psoriatičnih lezijah v primerjavi z neprizadeto kožo poveča koncentracija TNF.
Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Zdravilo Benepali je mogoče uporabiti kot monoterapijo, kadar bolnik ne prenese metotreksata ali kadar trajno zdravljenje z metotreksatom ni primerno.
• Always keep the container out of the sight and reach of children. 
• Vsebnik vedno shranjujte nedosegljivo otrokom.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch. 
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov proizvajalca,
Serious infections affect fewer than 1 in 100 patients treated with etanercept. 
Med zdravljenjem z etanerceptom so se resne okužbe pojavile pri manj kot 1 od 100 bolnikov.
From the start of part 2, the median time to flare was 116 days for patients who received etanercept and 28 days for patients who received placebo. 
Od začetka drugega dela študije je bil mediani čas do ponovnega izbruha bolezni 116 dni pri bolnikih na etanerceptu in 28 dni pri bolnikih na placebu.
• Anti-diabetic medicines: Tell your doctor if you or the child have diabetes or are taking medicines to treat diabetes. 
• Zdravila za zdravljenje sladkorne bolezni: Povejte zdravniku, če imate vi ali otrok sladkorno bolezen, ali če jemljete zdravila za zdravljenje sladkorne bolezni.
There have been reports of hypoglycaemia following initiation of etanercept in patients receiving medicinal products for diabetes, necessitating a reduction in anti-diabetic medicinal products in some of these patients. 
Po uvedbi etanercepta so pri bolnikih, ki so prejemali zdravila za zdravljenje sladkorne bolezni, so poročali o hipoglikemiji, zaradi katere je bilo treba pri nekaterih od teh bolnikov zmanjšati odmerek zdravila za zdravljenje sladkorne bolezni.
Significant advantages for etanercept in combination with methotrexate compared with etanercept monotherapy and methotrexate monotherapy were also observed after 24 months. 
Pomembne prednosti etanercepta v kombinaciji z metotreksatom pred monoterapijo z etanerceptom ali monoterapijo z metotreksatom so ugotovili tudi po 24 mesecih.
If any of the following happen, do not inject more Benepali. 
Če se pojavi kar koli od naslednjega, si zdravila Benepali ne smete več injicirati.
There have been rare reports of CNS demyelinating disorders in patients treated with etanercept (see section 4.8). 
Poročali so o redkih primerih demielinizirajočih obolenj centralnega živčnega sistema (CŽS) pri bolnikih, zdravljenih z etanerceptom (glejte poglavje 4.8).
• Signs of autoimmune reactions (where antibodies are made that may harm normal tissues in the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision; 
• znaki avtoimunskih reakcij (reakcije, pri katerih se tvorijo protitelesa, ki lahko poškodujejo normalna telesna tkiva), kot so bolečina, srbenje, oslabelost, težave z dihanjem, motnje mišljenja, zaznavanja ali vida;
In studies when adult patients received concurrent treatment with etanercept plus anakinra, a higher rate of serious infections compared to etanercept alone was observed and 2% of patients (3/139) developed neutropenia (absolute neutrophil count < 1,000/mm3). 
V študijah, v katerih so odrasli bolniki sočasno prejemali etanercept in anakinro, so opažali večjo stopnjo resnih okužb v primerjavi s samim etanerceptom in pri 2 % bolnikov (3/139) se je pojavila nevtropenija (absolutna koncentracija nevtrofilcev < 1.000/mm3).
In part 2, 6 of 25 (24%) patients remaining on etanercept experienced a disease flare compared to 20 of 26 (77%) patients receiving placebo (p = 0.007). 
V drugem delu je 6 od 25 (24 %) bolnikov, ki so ostali na etanerceptu, doživelo ponoven izbruh bolezni, v primerjavi z 20 od 26 (77 %) bolnikov, ki so v drugem delu prejemali placebo (p = 0,007).
Women of childbearing potential should consider the use of appropriate contraception to avoid becoming pregnant during Benepali therapy and for three weeks after discontinuation of therapy. 
Ženske v rodni dobi morajo razmisliti o uporabi ustrezne kontracepcije za preprečitev nosečnosti med zdravljenjem z zdravilom Benepali in še tri tedne po prenehanju zdravljenja.
Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. 
Ugotovili so, etanercept izboljša telesno funkcijo pri bolnikih s psoriatičnim artritisom in upočasni hitrost napredovanja okvar perifernih sklepov, merjenih z rentgenskim slikanjem, pri bolnikih s poliartikularnimi simetričnimi podvrstami bolezni.
Hold the pre-filled syringe at 45 degrees to the skin. 
Napolnjeno injekcijsko iglo nastavite na kožo pod kotom 45 stopinj.
These include rare reports of pancytopenia and very rare reports of aplastic anaemia. 
Ti vključujejo tudi redke primere pancitopenije in zelo redke primere aplastične anemije.
Long-term safety of etanercept monotherapy (n = 103), etanercept plus methotrexate (n = 294), or methotrexate monotherapy (n = 197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. 
Dolgoročno varnost zdravljenja z etanerceptom v monoterapiji (n = 103), zdravljenja z etanerceptom v kombinaciji z metotreksatom (n = 294) ali zdravljenja z metotreksatom v monoterapiji (n = 197) so ovrednotili za obdobje do 3 let na osnovi registra 594 otrok, starih od 2 do 18 let, z juvenilnim idiopatskim artritisom.
Serious allergic/anaphyla ctic reactions (including angioedema, bronchospasm), sarcoidosis 
resne alergijske/anafilaktičn e reakcije (vključno z angioedemom in bronhospazmom),
In a study of 49 adult patients with rheumatoid arthritis treated with etanercept, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations. 
Študija pri 49 odraslih bolnikih z revmatoidnim artritisom ni pokazala, da bi zdravljenje z etanerceptom zmanjšalo zapoznelo preobčutljivostno reakcijo, zmanjšalo raven imunoglobulinov ali spremenilo število efektorskih celic.
All patients and parents/caregivers should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or infections (e.g., persistent fever, sore throat, bruising, bleeding, and paleness) whilst on Benepali, they should seek immediate medical advice. 
Vse bolnike in starše/skrbnike je treba opozoriti, da morajo pri bolniku v primeru pojava znakov ali simptomov, ki kažejo na krvno diskrazijo ali okužbo (npr. trdovratna zvišana telesna temperatura, vnetje žrela, podplutbe, krvavitve in bledica), med zdravljenjem z zdravilom Benepali takoj poiskati zdravniško pomoč.
Some have occurred within a few weeks after initiating treatment with etanercept in patients who have underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis (see section 4.4). 
Nekatere okužbe so se pojavile nekaj tednov po začetku zdravljenja bolnikov z etanerceptom, ki so imeli poleg revmatoidnega artritisa tudi druga obolenja (npr. sladkorno bolezen, kongestivno srčno popuščanje, aktivne ali kronične okužbe v anamnezi) (glejte poglavje 4.4).
Additionally, studies have not been conducted to assess the effects of discontinuing or reducing the recommended dose of etanercept following its long-term use in patients with JIA. 
Pri bolnikih z JIA prav tako niso izvedli študij za ovrednotenje učinka prekinitve zdravljenja ali zmanjšanja priporočenega odmerka etanercepta po njegovi dolgotrajni uporabi.
If there is bleeding at the injection site, press a gauze pad over the injection site. 
Če opazite krvavitev na mestu injiciranja, na mesto injiciranja pritisnite gazo.
Whether used alone or in combination with methotrexate, Benepali can slow down the damage to your joints caused by the rheumatoid arthritis and improve your ability to do normal daily activities. 
Zdravilo Benepali samo ali v kombinaciji z metotreksatom lahko upočasni razvoj poškodb v sklepih zaradi revmatoidnega artritisa in izboljša sposobnost opravljanja vsakodnevnih opravil.
The dosage of etanercept is based on body weight for paediatric patients. 
Odmerjanje etanercepta za pediatrične bolnike temelji na njihovi telesni masi.
• Inflammatory bowel disease (IBD): There have been cases of IBD in patients with juvenile idiopathic arthritis (JIA) treated with etanercept. 
• Kronična vnetna črevesna bolezen (KVČB): Pri bolnikih z juvenilnim idiopatskim artritisom (JIA), ki so se zdravili z etanerceptom, so poročali o primerih KVČB.
Benepali should be discarded if not used within four weeks after removal from the refrigerator. 
Zdravilo Benepali zavrzite, če ga ne porabite v štirih tednih po odvzemu iz hladilnika.
In clinical studies, concurrent administration of abatacept and etanercept resulted in increased incidences of serious adverse events. 
V kliničnih študijah je sočasna uporaba abatacepta in etanercepta zvečala incidenco resnih neželenih učinkov.
However, your doctor may determine an alternative frequency at which to inject Benepali. 
Zdravnik vam lahko predpiše tudi drugačno pogostnost injiciranja zdravila Benepali.
Serious infections experienced by etanercept-treated patients included cellulitis, gastroenteritis, pneumonia, cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, diverticulitis and abscess. 
Med resnimi okužbami pri bolnikih, zdravljenih z etanerceptom, so bile celulitis, gastroenteritis, pljučnica, holecistitis, osteomielitis, gastritis, apendicitis, streptokokni fasciitis, miozitis, septični šok, divertikulitis in absces.
Your doctor may decide if you or the child need less anti-diabetic medicine while taking Benepali. 
Zdravnik lahko odloči, da boste vi ali otrok med jemanjem zdravila Benepali potrebovali manj zdravila za zdravljenje sladkorne bolezni.
After the 12-week double-blind treatment period, all patients received etanercept 0.8 mg/kg (up to 50 mg) once weekly for additional 24 weeks. 
Po 12-tedenskem obdobju dvojno slepega zdravljenja so vsi bolniki prejemali etanercept v odmerku 0,8 mg/kg (do 50 mg) enkrat na teden še dodatnih 24 tednov.
Approximately 15% of subjects who received etanercept achieved an ACR 70 response at month 3 and month 6 compared to fewer than 5% of subjects in the placebo arm. 
Približno 15 % bolnikov, zdravljenih z etanerceptom, je do 3. in 6. meseca doseglo odziv ACR 70, v primerjavi z manj kot 5 % tistih, ki so prejemali placebo.